Diverse patient trajectories during cytotoxic chemotherapy: Capturing longitudinal patient‐reported outcomes

作者：Amee D. Azad, Melih Yilmaz, Selen Bozkurt, James D. Brooks, Douglas W. Blayney, Tina Hernandez‐Boussard · 发表于：Cancer Medicine · 年份：2021 · DOI：10.1002/cam4.4124 · 被引用次数：11 · 研究领域：Cancer survivorship and care、Economic and Financial Impacts of Cancer、Cancer-related cognitive impairment studies

BACKGROUND: High-value cancer care balances effective treatment with preservation of quality of life. Chemotherapy is known to affect patients' physical and psychological well-being negatively. Patient-reported outcomes (PROs) provide a means to monitor declines in a patients' well-being during treatment. METHODS: We identified 741 oncology patients undergoing chemotherapy in our electronic health record (EHR) system who completed Patient-Reported Outcomes Measurement Information System (PROMIS) surveys during treatment at a comprehensive cancer center, 2013-2018. PROMIS surveys were collected before, during, and after chemotherapy treatment. Linear mixed-effects models were performed to identify predictors of physical and mental health scores over time. A k-mean cluster analysis was used to group patient PROMIS score trajectories. RESULTS: Mean global physical health (GPH) scores were 48.7 (SD 9.3), 47.7 (8.8), and 48.6 (8.9) and global mental health (GMH) scores were 50.4 (8.6), 49.5 (8.8), and 50.6 (9.1) before, during, and after chemotherapy, respectively. Asian race, Hispanic ethnicity, public insurance, anxiety/depression, stage III cancer, and palliative care were predictors of GPH and GMH decline. The treatment time period was also a predictor of both GPH and GMH decline relative to pre-treatment. Trajectory clustering identified four distinct PRO clusters associated with chemotherapy treatment. CONCLUSIONS: Patient-reported outcomes are increasingly used to help moni...